386 related articles for article (PubMed ID: 29797100)
1. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study.
Schwedt TJ; Alam A; Reed ML; Fanning KM; Munjal S; Buse DC; Dodick DW; Lipton RB
J Headache Pain; 2018 May; 19(1):38. PubMed ID: 29797100
[TBL] [Abstract][Full Text] [Related]
2. Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences.
Lipton RB; Munjal S; Alam A; Buse DC; Fanning KM; Reed ML; Schwedt TJ; Dodick DW
Headache; 2018 Oct; 58(9):1408-1426. PubMed ID: 30341895
[TBL] [Abstract][Full Text] [Related]
3. Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results from the American Migraine Prevalence and Prevention Study.
Lipton RB; Munjal S; Buse DC; Bennett A; Fanning KM; Burstein R; Reed ML
Headache; 2017 Jul; 57(7):1026-1040. PubMed ID: 28603893
[TBL] [Abstract][Full Text] [Related]
4. Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study.
Lipton RB; Munjal S; Buse DC; Alam A; Fanning KM; Reed ML; Schwedt TJ; Dodick DW
Headache; 2019 Sep; 59(8):1310-1323. PubMed ID: 31410844
[TBL] [Abstract][Full Text] [Related]
5. Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study.
Munjal S; Singh P; Reed ML; Fanning K; Schwedt TJ; Dodick DW; Buse DC; Lipton RB
Headache; 2020 Feb; 60(2):416-429. PubMed ID: 31837007
[TBL] [Abstract][Full Text] [Related]
6. Harris Poll Migraine Report Card: population-based examination of high-frequency headache/migraine and acute medication overuse.
Starling AJ; Cady R; Buse DC; Buzby M; Spinale C; Steinberg K; Lenaburg K; Kymes S
J Headache Pain; 2024 Feb; 25(1):26. PubMed ID: 38408888
[TBL] [Abstract][Full Text] [Related]
7. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
Buse DC; Serrano D; Reed ML; Kori SH; Cunanan CM; Adams AM; Lipton RB
Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
[TBL] [Abstract][Full Text] [Related]
8. Predicting Inadequate Response to Acute Migraine Medication: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
Lipton RB; Munjal S; Buse DC; Fanning KM; Bennett A; Reed ML
Headache; 2016 Nov; 56(10):1635-1648. PubMed ID: 27731896
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Acute Prescription Migraine Medication Use: Results From the CaMEO Study.
Hutchinson S; Lipton RB; Ailani J; Reed ML; Fanning KM; Adams AM; Buse DC
Mayo Clin Proc; 2020 Apr; 95(4):709-718. PubMed ID: 32247344
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with triptan use in episodic migraine: results from the American Migraine Prevalence and Prevention Study.
Chu MK; Buse DC; Bigal ME; Serrano D; Lipton RB
Headache; 2012 Feb; 52(2):213-23. PubMed ID: 22413150
[TBL] [Abstract][Full Text] [Related]
11. Identifying the factors underlying discontinuation of triptans.
Wells RE; Markowitz SY; Baron EP; Hentz JG; Kalidas K; Mathew PG; Halker R; Dodick DW; Schwedt TJ
Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
[TBL] [Abstract][Full Text] [Related]
12. Medication Overuse and Headache Burden: Results From the CaMEO Study.
Schwedt TJ; Buse DC; Argoff CE; Reed ML; Fanning KM; Hussar CR; Adams AM; Lipton RB
Neurol Clin Pract; 2021 Jun; 11(3):216-226. PubMed ID: 34476122
[TBL] [Abstract][Full Text] [Related]
13. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
Lipton RB; Serrano D; Nicholson RA; Buse DC; Runken MC; Reed ML
Headache; 2013; 53(10):1548-63. PubMed ID: 23992516
[TBL] [Abstract][Full Text] [Related]
14. Predictors of allodynia in persons with migraine: Results from the Migraine in America Symptoms and Treatment (MAST) study.
Dodick DW; Reed ML; Fanning KM; Munjal S; Alam A; Buse DC; Schwedt TJ; Lipton RB
Cephalalgia; 2019 Jun; 39(7):873-882. PubMed ID: 30732460
[TBL] [Abstract][Full Text] [Related]
15. Rates and reasons for discontinuation of triptans and opioids in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
Holland S; Fanning KM; Serrano D; Buse DC; Reed ML; Lipton RB
J Neurol Sci; 2013 Mar; 326(1-2):10-7. PubMed ID: 23394974
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.
Lipton RB; Hutchinson S; Ailani J; Reed ML; Fanning KM; Manack Adams A; Buse DC
Headache; 2019 Nov; 59(10):1762-1772. PubMed ID: 31544244
[TBL] [Abstract][Full Text] [Related]
17. The burden of medication overuse headache and patterns of switching and discontinuation among triptan users: a systematic literature review.
Deighton AM; Harris LA; Johnston K; Hogan S; Quaranta LA; L'Italien G; Coric V
BMC Neurol; 2021 Nov; 21(1):425. PubMed ID: 34727873
[TBL] [Abstract][Full Text] [Related]
18. Predictors of treatment-response to acute prescription medications in migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study.
Ezzati A; Buse DC; Fanning KM; Reed ML; Martin VT; Lipton RB
Clin Neurol Neurosurg; 2022 Dec; 223():107511. PubMed ID: 36395587
[TBL] [Abstract][Full Text] [Related]
19. Clinical and Demographical Characteristics of Patients with Medication Overuse Headache in Argentina and Chile: Analysis of the Latin American Section of COMOESTAS Project.
Shand B; Goicochea MT; Valenzuela R; Fadic R; Jensen R; Tassorelli C; Nappi G;
J Headache Pain; 2015; 16():83. PubMed ID: 26382855
[TBL] [Abstract][Full Text] [Related]
20. Prescription pain medications and chronic headache in Denmark: implications for preventing medication overuse.
Westergaard ML; Hansen EH; Glümer C; Jensen RH
Eur J Clin Pharmacol; 2015 Jul; 71(7):851-60. PubMed ID: 25967539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
